Merrill has QLT at neutral

QLT, Inc. was rated at neutral by Merrill Lynch analyst Hari Sambasivam after the company announced that it found no meaningful adverse events associated with Aczone in a six-month safety study. Aczone (dapsone gel 5%) is indicated for the topical treatment of acne vulgaris. The phase 4 study was undertaken by QLT to demonstrate that the topical formulation does not cause hemolysis and to further QLT's goal to have the testing requirement for G6PD deficiency removed from the label. Shares of the Vancouver, B.C.-based biopharmaceutical company were up 35 cents, or 4.23%, at $8.63. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.